Paratek Pharmaceuticals (TSPT) Receives Media Impact Rating of 0.15
News coverage about Paratek Pharmaceuticals (NASDAQ:TSPT) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.6693556024909 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
WARNING: “Paratek Pharmaceuticals (TSPT) Receives Media Impact Rating of 0.15” was published by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/paratek-pharmaceuticals-tspt-receives-media-impact-rating-of-0-15/1530300.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.